AR042472A1 - Preparaciones de liberacion controlada que comprenden tramadol y topiramato - Google Patents
Preparaciones de liberacion controlada que comprenden tramadol y topiramatoInfo
- Publication number
- AR042472A1 AR042472A1 ARP030104634A ARP030104634A AR042472A1 AR 042472 A1 AR042472 A1 AR 042472A1 AR P030104634 A ARP030104634 A AR P030104634A AR P030104634 A ARP030104634 A AR P030104634A AR 042472 A1 AR042472 A1 AR 042472A1
- Authority
- AR
- Argentina
- Prior art keywords
- hours
- tramadol
- preparation
- substrate
- effective amount
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A61K9/5047—Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Rheumatology (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Preparación farmacéutica oral adecuada para la dosificación cada 24 horas, que comprende un sustrato, en donde el sustrato comprende una cantidad farmacéuticamente eficaz de tramadol o una sal de dicho compuesto y una cantidad farmacéuticamente eficaz de topiramato, y en donde dicho sustrato puede estar revestido con un revestimiento de liberación controlada; dicha preparación tiene una proporción de disolución específica in vitro. Reivindicación 1: Una preparación farmacéutica oral de liberación controlada adecuada para la dosificación cada 24 horas, que comprende un sustrato que contiene una cantidad farmacéuticamente eficaz de tramadol o una sal de dicho compuesto y una cantidad farmacéuticamente eficaz de topiramato; dicha preparación tiene una proporción de disolución in vitro medida usando el Método de Paleta de la Ph. Eur.(Ph. Eur. Paddle Method) a 75 rmp en 900 ml de buffer de fosfato 0,05 M a 37sC y utilizando HPLC: entre 15 y 35% de tramadol liberado después de 1 hora; entre 28 y 48% de tramadol liberado después de 2 horas; entre 47 y 67% de tramadol liberado después de 4 horas; entre 68 y 88% de tramadol liberado después de 8 horas; entre 79 y 99% de tramadol liberado después de 12 horas; entre 86 y 105% de tramadol liberado después de 24 horas; en peso, en donde dicha preparación suministra un efecto terapéutico durante aproximadamente 24 horas luego de la administración oral. Reivindicación 17: Un proceso para la elaboración de una preparación farmacéutica oral según se reivindica en las reivindicaciones 1 a 16, que comprende mezclar clorhidrato de tramadol y topiramato con un sustrato adecuado.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02080325 | 2002-12-13 | ||
EP03075123 | 2003-01-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR042472A1 true AR042472A1 (es) | 2005-06-22 |
Family
ID=32598791
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030104634A AR042472A1 (es) | 2002-12-13 | 2003-12-15 | Preparaciones de liberacion controlada que comprenden tramadol y topiramato |
Country Status (15)
Country | Link |
---|---|
US (1) | US20060147527A1 (es) |
EP (1) | EP1572192A1 (es) |
JP (1) | JP2006514986A (es) |
KR (1) | KR20050075408A (es) |
AR (1) | AR042472A1 (es) |
AU (1) | AU2003296672A1 (es) |
BR (1) | BR0317177A (es) |
CA (1) | CA2506807A1 (es) |
CL (1) | CL2003002621A1 (es) |
MX (1) | MXPA05006210A (es) |
MY (1) | MY148475A (es) |
PL (1) | PL377351A1 (es) |
RU (1) | RU2005122008A (es) |
TW (1) | TW200427448A (es) |
WO (1) | WO2004054571A1 (es) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7927613B2 (en) | 2002-02-15 | 2011-04-19 | University Of South Florida | Pharmaceutical co-crystal compositions |
US7790905B2 (en) | 2002-02-15 | 2010-09-07 | Mcneil-Ppc, Inc. | Pharmaceutical propylene glycol solvate compositions |
EP1494998A2 (en) | 2002-03-01 | 2005-01-12 | University Of South Florida | Multiple-component solid phases containing at least one active pharmaceutical ingredient |
CA2489984A1 (en) | 2002-06-21 | 2003-12-31 | Transform Pharmaceuticals, Inc. | Pharmaceutical compositions with improved dissolution |
US8183290B2 (en) | 2002-12-30 | 2012-05-22 | Mcneil-Ppc, Inc. | Pharmaceutically acceptable propylene glycol solvate of naproxen |
EP2316456B1 (en) | 2003-04-29 | 2017-06-14 | Orexigen Therapeutics, Inc. | Compositions for affecting weight loss comprising an opioid antagonist and bupropion |
CA2572928A1 (en) | 2004-07-22 | 2006-02-26 | Amorepacific Corporation | Sustained-release preparations containing topiramate and the producing method thereof |
CN101068538A (zh) | 2004-11-04 | 2007-11-07 | 什诺波特有限公司 | 加巴喷丁前体药物持续释放口服剂型 |
WO2007025233A1 (en) | 2005-08-26 | 2007-03-01 | Regents Of The University Of Minnesota | Decellularization and recellularization of organs and tissues |
MXPA05011735A (es) * | 2005-11-01 | 2007-04-30 | Leopoldo Espinosa Abdala | Composiciones farmaceuticas que comprenden combinaciones de analgesicos y anticonvulsivantes para el tratamiento del dolor agudo y cronico. |
WO2007067341A2 (en) | 2005-11-22 | 2007-06-14 | Orexigen Therapeutics, Inc. | Compositions and methods for increasing insulin sensitivity |
US20190083399A9 (en) * | 2006-04-03 | 2019-03-21 | Isa Odidi | Drug delivery composition |
US8916195B2 (en) | 2006-06-05 | 2014-12-23 | Orexigen Therapeutics, Inc. | Sustained release formulation of naltrexone |
US9744137B2 (en) * | 2006-08-31 | 2017-08-29 | Supernus Pharmaceuticals, Inc. | Topiramate compositions and methods of enhancing its bioavailability |
KR101479324B1 (ko) * | 2006-11-09 | 2015-01-05 | 오렉시젠 세러퓨틱스 인크. | 신속하게 용해되는 중간층을 포함하는 층상의 약제학적 제형 |
MX343867B (es) | 2006-11-09 | 2016-11-25 | Orexigen Therapeutics Inc | Paquete de dosificacion unitaria y metodos para administrar medicaciones de perdida de peso. |
WO2008061226A2 (en) | 2006-11-17 | 2008-05-22 | Supernus Pharmaceuticals Inc. | Sustained-release formulations of topiramate |
CN102218044A (zh) * | 2006-12-04 | 2011-10-19 | 苏佩努斯制药公司 | 托吡酯的增强的立即释放制剂 |
DE102007026550A1 (de) * | 2007-06-08 | 2008-12-11 | Bayer Healthcare Ag | Extrudate mit verbesserter Geschmacksmaskierung |
CA2725930A1 (en) | 2008-05-30 | 2009-12-30 | Orexigen Therapeutics, Inc. | Methods for treating visceral fat conditions |
US20100003322A1 (en) * | 2008-07-03 | 2010-01-07 | Lai Felix S | Enteric coated hydrophobic matrix formulation |
DK2328561T3 (en) * | 2008-08-19 | 2016-02-08 | Adcock Ingram Intellectual Property Pty Ltd | Rate modulated administration of drugs from a three-layered tablet containing tramadol, diclofenac, paracetamol |
JP5783908B2 (ja) | 2008-12-19 | 2015-09-24 | スパーナス ファーマシューティカルズ インコーポレイテッド | 攻撃性を治療する方法 |
US9248123B2 (en) | 2010-01-11 | 2016-02-02 | Orexigen Therapeutics, Inc. | Methods of providing weight loss therapy in patients with major depression |
WO2011123497A1 (en) | 2010-03-31 | 2011-10-06 | Supernus Pharmaceuticals Inc. | Stabilized formulations of cns compounds |
CN103458935B (zh) | 2010-09-01 | 2016-08-03 | 明尼苏达大学董事会 | 使组织或器官再细胞化以提高其可移植性的方法 |
US10702485B2 (en) | 2011-07-09 | 2020-07-07 | Syntrix Biosystems Inc. | Compositions and methods for overcoming resistance to tramadol |
AU2013271622B2 (en) | 2012-06-06 | 2018-03-01 | Nalpropion Pharmaceuticals Llc | Methods of treating overweight and obesity |
US9290738B2 (en) | 2012-06-13 | 2016-03-22 | Miromatrix Medical Inc. | Methods of decellularizing bone |
US8652527B1 (en) * | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
WO2014151739A1 (en) | 2013-03-15 | 2014-09-25 | Miromatrix Medical Inc. | Use of perfusion decellularized liver for islet cell recellularization |
US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
US11278643B2 (en) | 2016-09-06 | 2022-03-22 | Mayo Foundation For Medical Education And Research | Use of resected liver serum for whole liver-engineering |
US11000488B2 (en) | 2019-03-22 | 2021-05-11 | Syntrix Biosystems Inc. | Treating pain using desmetramadol |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3652589A (en) * | 1967-07-27 | 1972-03-28 | Gruenenthal Chemie | 1-(m-substituted phenyl)-2-aminomethyl cyclohexanols |
US4513006A (en) * | 1983-09-26 | 1985-04-23 | Mcneil Lab., Inc. | Anticonvulsant sulfamate derivatives |
GB8601204D0 (en) * | 1986-01-18 | 1986-02-19 | Boots Co Plc | Therapeutic agents |
JPH0474515A (ja) * | 1990-07-13 | 1992-03-09 | Toray Ind Inc | 酸素吸収体 |
ES2120451T7 (es) * | 1991-09-06 | 2009-11-05 | Ortho-Mcneil-Janssen Pharmaceuticals, Inc. | Composicion que comprende un compuesto de tramadol y acetaminofeno, y su uso. |
MX9205106A (es) * | 1991-09-06 | 1993-05-01 | Johnson & Johnson | Composiciones que comprenden un material de tramadol y cualquiera de codeina, oxicodona o hidrocodona y su uso |
US5516803A (en) * | 1991-10-30 | 1996-05-14 | Mcneilab, Inc. | Composition comprising a tramadol material and a non-steroidal anti-inflammatory drug |
US5292534A (en) * | 1992-03-25 | 1994-03-08 | Valentine Enterprises, Inc. | Sustained release composition and method utilizing xanthan gum and an active ingredient |
IL109460A (en) * | 1993-05-10 | 1998-03-10 | Euro Celtique Sa | Controlled release formulation comprising tramadol |
GB9710699D0 (en) * | 1997-05-24 | 1997-07-16 | Danbiosyst Uk | Gastro-retentive controlled release system |
US5760007A (en) * | 1997-07-16 | 1998-06-02 | Ortho Pharmaceutical Corporation | Anticonvulsant derivatives useful in treating neuropathic pain |
MXPA02001820A (es) * | 1999-08-20 | 2003-07-14 | Johnson & Johnson | Composicion que comprende un material de tramadol y un farmaco anticonvulsivo. |
EP1508595B1 (en) * | 2001-10-25 | 2010-02-17 | Asahi Kasei Chemicals Corporation | Polyphenylene sulfide resin composition |
EP1364649A1 (en) * | 2002-05-23 | 2003-11-26 | Cilag AG | Adduct of topiramate and tramadol hydrochioride and uses thereof |
-
2003
- 2003-12-12 KR KR1020057008630A patent/KR20050075408A/ko not_active Application Discontinuation
- 2003-12-12 BR BR0317177-9A patent/BR0317177A/pt not_active IP Right Cessation
- 2003-12-12 JP JP2005502442A patent/JP2006514986A/ja not_active Withdrawn
- 2003-12-12 MX MXPA05006210A patent/MXPA05006210A/es not_active Application Discontinuation
- 2003-12-12 MY MYPI20034787A patent/MY148475A/en unknown
- 2003-12-12 WO PCT/EP2003/014474 patent/WO2004054571A1/en active Application Filing
- 2003-12-12 AU AU2003296672A patent/AU2003296672A1/en not_active Abandoned
- 2003-12-12 US US10/538,946 patent/US20060147527A1/en not_active Abandoned
- 2003-12-12 RU RU2005122008/15A patent/RU2005122008A/ru not_active Application Discontinuation
- 2003-12-12 CA CA002506807A patent/CA2506807A1/en not_active Abandoned
- 2003-12-12 PL PL377351A patent/PL377351A1/pl not_active Application Discontinuation
- 2003-12-12 EP EP03813140A patent/EP1572192A1/en not_active Withdrawn
- 2003-12-12 TW TW092135209A patent/TW200427448A/zh unknown
- 2003-12-15 CL CL200302621A patent/CL2003002621A1/es unknown
- 2003-12-15 AR ARP030104634A patent/AR042472A1/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
MY148475A (en) | 2013-04-30 |
BR0317177A (pt) | 2005-10-25 |
CA2506807A1 (en) | 2004-07-01 |
RU2005122008A (ru) | 2006-02-10 |
US20060147527A1 (en) | 2006-07-06 |
JP2006514986A (ja) | 2006-05-18 |
KR20050075408A (ko) | 2005-07-20 |
PL377351A1 (pl) | 2006-01-23 |
MXPA05006210A (es) | 2005-08-19 |
EP1572192A1 (en) | 2005-09-14 |
CL2003002621A1 (es) | 2005-03-11 |
TW200427448A (en) | 2004-12-16 |
AU2003296672A1 (en) | 2004-07-09 |
WO2004054571A1 (en) | 2004-07-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR042472A1 (es) | Preparaciones de liberacion controlada que comprenden tramadol y topiramato | |
RU2005115855A (ru) | Композиция трамадола продлонгированного высвобождением с 24-часовым действием | |
RS50056B (sr) | Kompozicije oksikodona sa kontrolisanim oslobađanjem | |
EA200700049A1 (ru) | Препаративные формы оральных лекарственных форм мемантина с модифицированным высвобождением | |
DK293087A (da) | Fast dihydrocodeinpraeparat med reguleret afgivelse | |
DE3773468D1 (de) | Hydromorphon-zusammensetzung mit gesteuerter wirkstofffreisetzung. | |
BR0008590A (pt) | Agente de entrega polimérico, composição, formade unidade de dosagem, método para administrarum agente biologicamente ativo a um animalnecessitando o agente, método para preparar umacomposição; e composto | |
AR028504A2 (es) | Combinacion, metodo para mejorar la apariencia corporal de un mamifero, composicion farmaceutica, uso de dicha combinacion para la preparacion de un medicamento para la prevencion, demora de progreso, o tratamiento de desordenes metabolicos, y paquete comercial | |
BR9510168A (pt) | Composto poliaminoácido composição forma unitária de dosagem e método par epreparar uma composição | |
AR085778A2 (es) | Forma de dosis solida enterica revestida, que comprende acido micofenolico o sal micofenolato | |
RS52577B (en) | ONE-DAY OXYCODON FORMULATIONS | |
BR0214757A (pt) | Formulações farmacêuticas de derivados de platina | |
ATE424810T1 (de) | Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung | |
HN1999000183A (es) | Preparado farmaceuticos de moxifloxacina | |
PE20021017A1 (es) | Composicion parenteral reconstituible | |
ECSP066318A (es) | Composición para la liberación de una base debil por un periodo extendido de tiempo | |
ES2168241T1 (es) | Preparacion farmaceutica que contiene tolperisona para administrar por via oral. | |
HUP0004780A2 (hu) | Prosztaglandin agonisták felhasználása merevedési rendellenességek vagy impotencia kezelésében | |
AR043536A1 (es) | Composicion farmaceutica que comprende acido 5-metil-2-(2´-cloro-6´-fluoroanilino)fenilacetico | |
BR9911756A (pt) | Composto, uso de um secretagogo do hormÈnio do crescimento ou um seu sal farmaceuticamente aceitável, composição farmacêutica, método para estimular a liberação do hormÈnio do crescimento pela pituitária de um mamìfero, e, uso de um composto | |
RS50058B (sr) | Kompozicije oksikodona sa kontrolisanim oslobađanjem | |
PE20011042A1 (es) | Uso de glutamina para la prevencion de diarrea de inicio tardio inducida por irinotecan | |
YU20050409A (sh) | Kompozicije oksikodona sa kontrolisanim oslobađanjem | |
BR0312333A (pt) | Terapia de combinação e agente para sua execução | |
AR017240A2 (es) | COMPOSICIONES DE ÁCIDO ALENDRoNICO , SUS SALES O ESTERES |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |